[
  {
    "ts": "2025-12-10T12:12:49+00:00",
    "headline": "Did Humana’s Lowered Outlook and Mark Cuban Drug Talks Just Shift Humana's (HUM) Investment Narrative?",
    "summary": "Earlier this month, Humana cut its full-year earnings outlook, citing ongoing pressure in its Medicare Advantage business amid a challenging reimbursement and cost backdrop. At the same time, attention has turned to a possible pharmacy tie-up with Mark Cuban’s low-cost drug venture, which could reshape how Humana’s CenterWell division sources and delivers medications. Next, we’ll examine how the lowered earnings outlook and potential Mark Cuban pharmacy partnership reshape Humana’s...",
    "url": "https://finance.yahoo.com/news/did-humana-lowered-outlook-mark-121249426.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "c4b08acc-2e88-3cca-bcd3-d38a94a1e947",
      "content": {
        "id": "c4b08acc-2e88-3cca-bcd3-d38a94a1e947",
        "contentType": "STORY",
        "title": "Did Humana’s Lowered Outlook and Mark Cuban Drug Talks Just Shift Humana's (HUM) Investment Narrative?",
        "description": "",
        "summary": "Earlier this month, Humana cut its full-year earnings outlook, citing ongoing pressure in its Medicare Advantage business amid a challenging reimbursement and cost backdrop. At the same time, attention has turned to a possible pharmacy tie-up with Mark Cuban’s low-cost drug venture, which could reshape how Humana’s CenterWell division sources and delivers medications. Next, we’ll examine how the lowered earnings outlook and potential Mark Cuban pharmacy partnership reshape Humana’s...",
        "pubDate": "2025-12-10T12:12:49Z",
        "displayTime": "2025-12-10T12:12:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f6ed28f0d41f879bd5a978786002c2db",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Hmp2bSpG9df53vmcWkUJ8g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f6ed28f0d41f879bd5a978786002c2db.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KUEpq9U8lIeW2zfadEuUSw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f6ed28f0d41f879bd5a978786002c2db.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/did-humana-lowered-outlook-mark-121249426.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/did-humana-lowered-outlook-mark-121249426.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HUM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]